After intravenous thrombolysis therapy for acute cerebral infarction(ACI),it is necessary to continue receiving anti-platelet therapy to prevent infarction recurrence and other cardiovascular and cerebrovascular events.Tirofiban is a commonly used anti-platelet drug,which is more widely used in patients with ACI.It has anti-platelet aggregation,anti-inflammatory and other effects,can reduce thromboembolic events,and does not increase the risk of bleeding.At this stage,the application of tirofiban after intravenous thrombolytic therapy for ACI is relatively mature.No matter it is combined with double anti-platelet(DAPT),heparin and other drugs,it is safe and effective,and the safety of low dose tirofiban is higher.The comprehensive anti-thrombotic regimen based on tirofiban may be the first choice after intravenous thrombolytic treatment of ACI patient.
维普
万方数据